GlassScriptPhysician profile
Lesly Dessieux
NPI 1336215490
$4,922.96
in general payments reported to CMS, 2019-2025
36 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $788 · 2021: $796 · 2022: $791 · 2023: $611 · 2024: $729 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.44 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,058.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $495.55 | 2021-2024 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $459.25 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.48 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $336.93 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $336.92 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $273.07 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $214.79 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $143.55 | 2020-2023 | Nexletol, Contrave |
| Exact Sciences Corporation | $115.84 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $105.21 | 2024-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $97.16 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $73.50 | 2020-2021 | |
| Shield Therapeutics INC | $72.08 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $68.44 | 2023-2024 | Quviviq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.89 | 2020-2024 | |
| Amarin Pharma, INC. | $60.08 | 2020-2021 | |
| Abbott Laboratories | $57.47 | 2019-2024 | Freestyle Libre 3 |
| Tolmar, INC. | $57.31 | 2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $53.86 | 2019-2022 | |
| Medtronic, INC. | $51.89 | 2024-2025 | Venaseal |
| Corcept Therapeutics | $43.64 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $37.89 | 2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $35.01 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $32.70 | 2024-2025 | Zoryve |
| Antares Pharma, INC. | $31.27 | 2021-2024 | Xyosted |
| Dexcom, INC. | $28.65 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $25.77 | 2025 | Voquezna |
| Verity Pharmaceuticals INC. | $20.05 | 2025 | Tlando |
| Halozyme INC | $17.88 | 2023 | |
| Shire North American Group INC | $17.09 | 2019 | |
| Astellas Pharma US INC | $16.26 | 2023 | Veozah |
| Ethicon US, LLC | $15.72 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.10 | 2024 | Caplyta |
| Genentech USA, INC. | $13.06 | 2019 | |
| Mayne Pharma Commercial LLC | $5.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesly Dessieux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.